BioNTech (NASDAQ:BNTX) Upgraded at Hsbc Global Res

Hsbc Global Res upgraded shares of BioNTech (NASDAQ:BNTX) from a hold rating to a strong-buy rating in a report issued on Friday morning, Zacks.com reports.

BNTX has been the topic of several other reports. BMO Capital Markets lowered their target price on shares of BioNTech from $123.00 to $122.00 and set an outperform rating on the stock in a research report on Tuesday, May 7th. TD Cowen upped their target price on shares of BioNTech from $95.00 to $98.00 and gave the stock a hold rating in a research report on Tuesday, May 7th. HC Wainwright restated a buy rating and set a $113.00 target price on shares of BioNTech in a research report on Thursday, August 1st. HSBC upgraded shares of BioNTech from a hold rating to a buy rating in a research report on Friday. Finally, Evercore ISI began coverage on shares of BioNTech in a report on Tuesday, May 14th. They issued an inline rating and a $100.00 price target on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of Hold and an average target price of $110.40.

BioNTech Stock Performance

Shares of BioNTech stock traded up $1.14 on Friday, reaching $79.50. 740,558 shares of the stock were exchanged, compared to its average volume of 701,449. BioNTech has a 1-year low of $76.53 and a 1-year high of $125.83. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average price of $87.74 and a two-hundred day moving average price of $90.63. The firm has a market capitalization of $18.90 billion, a PE ratio of 159.00 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The firm had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. During the same quarter last year, the firm earned ($0.86) earnings per share. The company’s revenue was down 23.3% compared to the same quarter last year. As a group, research analysts anticipate that BioNTech will post -2.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several institutional investors and hedge funds have recently modified their holdings of the company. Caprock Group LLC purchased a new position in shares of BioNTech during the second quarter valued at approximately $206,000. Gallacher Capital Management LLC lifted its stake in shares of BioNTech by 12.1% during the second quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company’s stock valued at $294,000 after buying an additional 395 shares during the period. Candriam S.C.A. lifted its stake in shares of BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after buying an additional 418,695 shares during the period. TD Asset Management Inc lifted its stake in shares of BioNTech by 6.1% during the second quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after buying an additional 435 shares during the period. Finally, Investmentaktiengesellschaft Fuer Langfristige Investoren TGV lifted its stake in shares of BioNTech by 41.4% during the second quarter. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV now owns 20,500 shares of the company’s stock valued at $1,647,000 after buying an additional 6,000 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.